Larotrectinib (Vitrakvi®)
Entrectinib (Rozlytrek®) and larotrectinib (Vitrakvi®) are used for the treatment of solid tumours displaying a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. A Managed Access Protocol (MAP) is in place for these medicines, reimbursed under the High Tech Arrangement. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of entrectinib or larotrectinib for the treatment of solid tumours displaying an NTRK gene fusion under the High Tech Arrangement.
Applications for reimbursement approval for entrectinib or larotrectinib for the treatment of solid tumours displaying an NTRK gene fusion under the High Tech Arrangement will only be considered from consultant medical oncologists, registered with the Irish Medical Council, who have agreed to the terms of this MAP and been approved by the HSE. The approved consultant must submit an application for individual reimbursement approval for each patient.
A copy of the MAP for entrectinib (Rozlytrek®) and larotrectinib (Vitrakvi®) for the treatment of solid tumours displaying an NTRK gene fusion, and the application form for individual reimbursement approval can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.